This study is designed to assess the effect of root extract of P. ginseng on kidney tissue injury attributed to cisplatin and its molecular mechanism involved in this process in the AKI rat model. Twenty-four male Wistar rats were randomly allocated into 4 experimental groups including: the control group, the cisplatin group, the extract 100 mg/kg group, and the extract 200 mg/kg group. The duration of the investigation was 7 days, and all rats except the control group received a single dose of 10 mg/kg cisplatin on the 4th day. Our findings exhibited a significant reduction in blood concentration of creatinine in extract groups compared to the cisplatin group. In the cisplatin group, severe renal histopathological alterations were observed compared to the control group. In extract groups, significantly less tissue damage was observed than in the cisplatin group. Ginseng extract 200 showed minimal tissue damage as compared to extract 100. The expression of p21, p27, p53, TIMP2, IGFBP7, and NF-κB decreased significantly in extract groups compared to the cisplatin group. Our findings displayed amelioration of cisplatin-induced AKI and dose-dependent decrease of the NF-κB gene expression and cell death-inducing genes by administration of P. ginseng extract.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-025-87447-0DOI Listing

Publication Analysis

Top Keywords

cisplatin group
20
ginseng extract
12
control group
12
group extract
12
extract groups
12
extract
10
group
10
cisplatin-induced aki
8
group cisplatin
8
groups compared
8

Similar Publications

This study is designed to assess the effect of root extract of P. ginseng on kidney tissue injury attributed to cisplatin and its molecular mechanism involved in this process in the AKI rat model. Twenty-four male Wistar rats were randomly allocated into 4 experimental groups including: the control group, the cisplatin group, the extract 100 mg/kg group, and the extract 200 mg/kg group.

View Article and Find Full Text PDF

Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently.

View Article and Find Full Text PDF

Evaluating Cetuximab Regimens in Head and Neck Cancer: Insights from a Retrospective Cohort Study.

Cancers (Basel)

January 2025

Division of Hematology-Oncology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 82445, Taiwan.

Background/objectives: The aim of this study is to assess the effectiveness of cetuximab combination therapy in patients with recurrent or metastatic head and neck cancer treated at a hospital in Southern Taiwan.

Methods: This study analyzed a retrospective cohort of 67 patients who were treated between January 2020 and May 2024 with two cetuximab regimens, cetuximab combined with cisplatin and 5-Fu, which were administered every four weeks during hospitalization (CPF4) and every two weeks as outpatient treatment (CPF2), respectively. The clinical outcomes, including overall survival and progression-free survival (PFS), were compared across the treatment regimens and age groups using Kaplan-Meier survival curves and Cox proportional hazard models.

View Article and Find Full Text PDF

Despite the association between aberrant TGFBI expression and tumors development found in various cancer types, the role of TGFBI in diffuse large B-cell lymphoma (DLBCL) progression is not clear. This study attempted to reveal how TGFBI impacts malignant progression and cisplatin sensitivity in DLBCL. Bioinformatics and qRT-PCR were used to analyze expression of TGFBI.

View Article and Find Full Text PDF

Lutein, a non-provitamin A carotenoid, reduces cisplatin-induced cardiotoxicity.

Prostaglandins Other Lipid Mediat

January 2025

Department of Pharmacology, Vocational School of Health Services, Adıyaman University, Adıyaman, Turkey. Electronic address:

Cardiovascular complications resulting from cisplatin (CS) are a significant factor that can disrupt the treatment plan associated with this chemotherapy. This information led us to investigate the effectiveness of lutein (LT), which has antioxidant effects, in preventing CS-induced cardiotoxic effects. After 28 rats were randomly divided into four equal groups, saline (1ml/day) was administered to the control group, LT (100mg/kg/day) to the LT group, CS (10mg/kg) to the CS group, and active agents in the LT and CS groups were administered to the CS + LT group in the same dose and manner.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!